Global Cannabis Applications Corp. (“GCAC” or the “Company”) (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative data technologies for the medical cannabis industry, is pleased to announce that it has published a White Paper on its medical cannabis Citizen Green technology platform and token economy. The White Paper is available for download on www.cannappscorp.com.

GCAC has published its White Paper titled ‘A Global Community for Medicinal Cannabis Users, Researchers and Practitioners.’ The White Paper outlines GCAC’s Citizen Green information technology development plan and market development strategy for the blockchain application, mobile applications, artificial intelligence and token economy. Written by a team of internationally recognized experts, the White Paper outlines a set of solutions that creates a global, trusted and secure data ecosystem on medical cannabis product efficacy.


Blockchain technology was selected as the most secure and transparent way to record, view and transfer cannabis data submitted by the users and from clinical studies. The combination of selected blockchain networks – Ethereum and NEM – ensures the highest level of data protection, immutable proof of ownership and the ability to monetize this data. GCAC’s mobile applications will capture anecdotal medical cannabis data inputs and use proprietary artificial intelligence and predictive analysis to validate this information against clinical study data inside of the CannaCube database for the purpose of establishing what specific medical cannabis products have a high efficacy rate for treating target ailments (see ‘Pain to Strain’ press release dated June 13, 2017). App users will earn reward tokens, called the Citizen Green Token (CGT), for their data inputs as calculated by the system analytics. CGTs will also be used to fund medical clinical study data from the GCAC treasury through a dedicated portal in the Citizen Green Community (see ‘GCAC To Participate in Medical Cannabis Study…’ press release dated March 28, 2018). CGTs earned or purchased will be stored in an e-wallet, redeemable for medical cannabis related products. This enables an economically viable ecosystem in which users have strong incentives to share their data for the reward tokens.

“For first time in history, producers of medical cannabis products, regulators and retailers will have access to accurate and immutable data that is verified and can help them focus on creating medical cannabis products based on the extensive scientific and constantly updated research,” said GCAC CEO Brad Moore. “The use of Citizen Green Token crypto-currency incentivizes users to contribute and share their knowledge through the use of cutting-edge technologies to contribute to solve the key problem of helping put better medical cannabis products on the shelf. As a true utility token, the CGT crypto-currency is available to all contributors and users of medical cannabis data.”

Citizen Green Tokens provide a set of utility functions being developed by GCAC:

  • Access rights to experiential, clinical and analysed data stored on the platform.
  • Discounts on the platform fees that are charged to participants to access data and which are normally paid using fiat currency.
  • Rewards for active contributors and users of the medicinal cannabis data to incentivize quality data production.
  • Access or discount tokens for the services or platforms of GCAC partners, such as dispensaries, pharmaceutical companies and governments.
  • Exclusive access to certain platform functions such as personalized and artificial intelligence data.
  • Discounts on the purchase of medicinal cannabis products, which will be a key element of the rewards program supported commercially and technically by dispensaries.

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more information about the Company, please visit online at www.cannappscorp.com, or review its profiles at www.sedar.com and on the Canadian Securities Exchange’s website (www.thecse.com).

To schedule an interview, please contact:

Bradley Moore
Chief Executive Officer
Telephone: 514.561.9091
Email: bmoore@cannappscorp.com

For more information, please contact:

Corporate Communications Canada & Europe
Telephone: 1.855.269.9554
Email: info@cannappscorp.com
www.cannappscorp.com

Corporate Communications United States
Hayden IR
Telephone: 1.917.658.7878
Email: hart@haydenir.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

SOURCE: Global Cannabis Applications Corp.

Click here to connect with Global Cannabis Applications Corp. and receive an Investor’s Presentation.

Source: www.accesswire.com

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less